Newron Pharmaceuticals S.p.A. (NWPHF) Stock Price & Analysis
Newron Pharmaceuticals S.p.A. (NWPHF) — price $20.00 (0.00%), as of the Oct 2, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Newron Pharmaceuticals S.p.A. · NWPHF
Newron Pharmaceuticals S.p.A. is a clinical-stage biopharmaceutical company focused on developing therapies for central and peripheral nervous system disorders and pain. The company's pipeline includes Xadago for Parkinson's disease, Evenamide for Schizophrenia, and Ralfinamide for neuropathic pain.
Price as of Oct 2, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $20.00 | |
| Change on the day | 0.00% | |
| 52-week range | $9.36 – $20.00 | |
| Shares traded on the day | 986 |
Price & events
Other perspectives
Council score for Newron Pharmaceuticals S.p.A. (NWPHF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 4, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the NWPHF film — every key number, told as a short cinematic story
~2 min · open the film
What is Newron Pharmaceuticals S.p.A. (NWPHF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Newron Pharmaceuticals S.p.A. (NWPHF) is the company analyzed here. It employs 22 people and is led by Stefan Weber. In Q4 FY2025 it reported revenue of $15M and net income of -$15M.
What do the latest results show for Newron Pharmaceuticals S.p.A. (NWPHF)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of $15M. Against analyst estimates the company has EPS beat 1 of 3 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | $15M | -$15M | -$0.74 (diluted) |
| Q2 FY2025 | $7M | -$41,078.925 | -$0.0021 (diluted) |
| Q4 FY2024 | $54M | $29M | $1.54 (diluted) |
| Jun 2024 | $4M | -$11M | -$0.58 (diluted) |
What are the financial strengths and risks for Newron Pharmaceuticals S.p.A. (NWPHF)?
Short answer
The distress and quality screens read Altman Z 7.01 · Piotroski F 3. Trailing ratios: ROE 277.9% · ROA -33.1% · current ratio 0.76 · earnings yield -4.9% · free-cash-flow yield 11.4%.
What should you watch next at Newron Pharmaceuticals S.p.A. (NWPHF)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $13.82M · EPS -1.49 · 2 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $13.82M
- EPS estimate
- $-1.49
Measured against a quoted price of $20.00 (as of Oct 2, 2026).
What has been published about Newron Pharmaceuticals S.p.A. (NWPHF)?
What Investors Ask About Newron Pharmaceuticals S.p.A. (NWPHF)
These answers are editorial: 1 of these 8 answers is drawn from the NWPHF research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is NWPHF a good stock to buy?
Stock Expert AI does not rate NWPHF buy, sell or hold. Newron Pharmaceuticals S.p.A. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the NWPHF stock price today?
The last price recorded on this page for Newron Pharmaceuticals S.p.A. (NWPHF) is $20.00, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for NWPHF?
The main risks for Newron Pharmaceuticals S.p.A. are typical of a clinical-stage biopharmaceutical company. A primary concern is the inherent uncertainty and high failure rate of clinical trials; negative or inconclusive results for Evenamide or Ralfinamide could significantly impact the company's valuation and future prospects.
What are the key factors to evaluate for NWPHF?
Evaluate NWPHF on fundamentals, analyst consensus, and risk factors. Dividend Policy: The company does not pay a dividend, consistent with a growth-oriented strategy focused on reinvesting capital into pipeline development. Not financial advice.
How frequently does NWPHF data refresh on this page?
NWPHF's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven NWPHF's recent stock price performance?
Newron Pharmaceuticals S.p.A. (NWPHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established product Xadago for Parkinson's disease, providing an existing revenue stream and market presence. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NWPHF overvalued or undervalued right now?
Newron Pharmaceuticals S.p.A. (NWPHF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NWPHF before investing?
Before investing in Newron Pharmaceuticals S.p.A. (NWPHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (16 figures)
The 16 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 7 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $20.00 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T21:34:42.602Z. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) · quote | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 986 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q4 FY2025 | $15M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q4 FY2025 | -$15M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q4 FY2025 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 9 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $9.36 – $20.00 | UNRECORDED | Stored company-profile observation — Captured 2026-09-23 · Expired observation | |
id.employees | Employees | 22 | UNRECORDED | Stored company-profile observation — Captured 2026-09-23 · Expired observation | |
id.ceo | Chief executive | Stefan Weber | UNRECORDED | Stored company-profile observation — Captured 2026-09-23 · Expired observation | |
earn.history | Reported versus estimated, recent quarters | EPS beat 1 of 3 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-02 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 7.01 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 277.9% · ROA -33.1% · current ratio 0.76 · earnings yield -4.9% · free-cash-flow yield 11.4% | — | UNRECORDED | Stored key metrics — Date unknown |
earn.estimates | Analyst estimates, next fiscal year | FY2026 revenue $13.82M · EPS -1.49 · 2 analysts | UNRECORDED | Stored analyst estimates — Captured 2026-10-04 | |
earn.est_revenue | Revenue estimate, FY2026 | $13.82M | UNRECORDED | Stored analyst estimates — Captured 2026-10-04 | |
earn.est_eps | EPS estimate, FY2026 | $-1.49 | UNRECORDED | Stored analyst estimates — Captured 2026-10-04 |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.